Business Context and Reporting Period
This Form 8-K, dated May 31, 2026, reports a significant leadership transition at West Pharmaceutical Services, Inc. The filing announces the appointment of Michel Lagarde as President and Chief Executive Officer (CEO), effective August 31, 2026, succeeding Eric M. Green, who is retiring. Upon Lagarde's start date, Robert F. Friel will assume the role of Chair of the Board.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and governance changes.
Material Changes
The primary material change is the succession of the CEO and the associated compensation structure:
- Leadership Change: Michel Lagarde replaces Eric M. Green as CEO and President, effective August 31, 2026.
- Board Composition: Mr. Green will resign from the Board, and Mr. Lagarde will be appointed to fill the vacancy.
- Chairmanship: Lead Independent Director Robert F. Friel will become Chair of the Board.
Guidance, Outlook, and Compensation Details
The filing details the employment agreement and compensation package for the new CEO, Mr. Lagarde:
- Base Salary: $1,175,000 annually, subject to review starting in 2027.
- Annual Incentive: Target award of 125% of salary ($1,468,750), prorated for 2026.
- Long-Term Incentives (LTI): 2026 awards valued at $8,611,111 (prorated from a $10,000,000 target), split 50% Performance Share Units (PSUs), 25% Restricted Stock Units (RSUs), and 25% Stock Options.
- Inducement Equity: A one-time grant with a maximum aggregate value of $10,000,000, consisting of:
- Sign-on Grant: $6,875,000.
- Matching Grant: Based on personal stock purchases up to $2,500,000, with a 50% RSU match and 75% stock option match.
- Severance: Includes 12 months of salary continuation for involuntary termination without Cause. In the event of a Change in Control, severance includes a lump sum equal to two times salary plus prior three-year average bonus, 36 months of benefits, and full vesting of LTI awards.
The filing contains no forward-looking financial guidance or operational outlook beyond the leadership transition.
Investor Verification Checklist
- Verify the exact start date of August 31, 2026, for the transition of duties.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the vesting schedules and performance metrics for the $8.6 million LTI grant and the $10 million inducement package.
- Monitor the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.